These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

965 related articles for article (PubMed ID: 19958638)

  • 1. [Clinical and histological features of non-alcoholic fatty liver disease].
    Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chan AW; Choi PC; Chim AM; Chu S; Chan FK; Sung JJ; Chan HL
    Aliment Pharmacol Ther; 2009 Feb; 29(4):387-96. PubMed ID: 19035982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between morphological diagnosis of NASH (non-alcoholic steatohepatitis) and liver function tests in a group of patients with morbid obesity].
    Chavarría-Arciniega S; López-Alvarenga JC; Uribe-Uribe NO; Herrera-Hernández M; González-Barranco J
    Rev Invest Clin; 2005; 57(4):505-12. PubMed ID: 16315634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
    Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S
    Hepatology; 2008 Sep; 48(3):792-8. PubMed ID: 18752331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
    Sorbi D; Boynton J; Lindor KD
    Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.
    Huang MA; Greenson JK; Chao C; Anderson L; Peterman D; Jacobson J; Emick D; Lok AS; Conjeevaram HS
    Am J Gastroenterol; 2005 May; 100(5):1072-81. PubMed ID: 15842581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.
    Palekar NA; Naus R; Larson SP; Ward J; Harrison SA
    Liver Int; 2006 Mar; 26(2):151-6. PubMed ID: 16448452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
    Ito S; Yukawa T; Uetake S; Yamauchi M
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values.
    Amarapurkar DN; Patel ND
    Trop Gastroenterol; 2004; 25(3):130-4. PubMed ID: 15682660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis.
    Tsang SW; Ng WF; Wu BP; Chow DA; Li ET; Wong TC
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):116-21. PubMed ID: 16706822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement.
    Dixon JB; Bhathal PS; O'Brien PE
    Obes Surg; 2006 Oct; 16(10):1278-86. PubMed ID: 17059735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women.
    Kunde SS; Lazenby AJ; Clements RH; Abrams GA
    Hepatology; 2005 Sep; 42(3):650-6. PubMed ID: 16037946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes.
    Rodríguez-Hernández H; Gonzalez JL; Márquez-Ramirez MD; Flores-Hernandez M; Rodríguez-Morán M; Guerrero-Romero F
    Eur J Gastroenterol Hepatol; 2008 May; 20(5):399-403. PubMed ID: 18403941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.
    Wong VW; Wong GL; Choi PC; Chan AW; Li MK; Chan HY; Chim AM; Yu J; Sung JJ; Chan HL
    Gut; 2010 Jul; 59(7):969-74. PubMed ID: 20581244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease.
    Haukeland JW; Konopski Z; Linnestad P; Azimy S; Marit Løberg E; Haaland T; Birkeland K; Bjøro K
    Scand J Gastroenterol; 2005 Dec; 40(12):1469-77. PubMed ID: 16293559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
    Ong JP; Elariny H; Collantes R; Younoszai A; Chandhoke V; Reines HD; Goodman Z; Younossi ZM
    Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
    Satapathy SK; Sakhuja P; Malhotra V; Sharma BC; Sarin SK
    J Gastroenterol Hepatol; 2007 May; 22(5):634-8. PubMed ID: 17444848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.